0001209191-22-059438.txt : 20221202 0001209191-22-059438.hdr.sgml : 20221202 20221202170032 ACCESSION NUMBER: 0001209191-22-059438 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221201 FILED AS OF DATE: 20221202 DATE AS OF CHANGE: 20221202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bellinger Andrew CENTRAL INDEX KEY: 0001864116 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 221442825 MAIL ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-01 0 0001840574 Verve Therapeutics, Inc. VERV 0001864116 Bellinger Andrew C/O VERVE THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 601 BOSTON MA 02215 0 1 0 0 CSO & CMO Common Stock 2022-12-01 4 S 0 865 22.95 D 6629 D Represents shares acquired pursuant to the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on November 30, 2022 in a transaction exempt pursuant to Rule 16b-3(c). The shares were automatically sold through an automatic sale program in which the Reporting Person elected to participate on May 1, 2022. The sale does not represent a discretionary trade by the Reporting Person. /s/ Andrew Ashe, as Attorney-in-Fact for Andrew Bellinger 2022-12-02